Diagnostic tests that help to individualize treatment for breast and colon cancer patients.
The Oncotype DX® Breast Cancer Assay is a diagnostic test that analyzes a panel of 21 genes. Oncotype DX® was developed for women with early-stage invasive breast cancer, with hormone estrogen receptor (ER) positive and HER-2 negative, and helps to identify whether chemotherapy should or should not be added to their treatment. It also quantifies the likelihood of breast cancer recurrence.
The Oncotype DX® Breast Cancer Test for DCIS (Ductal Carcinoma In Situ) is a 12 gene assay that predicts the risk of local recurrence (DCIS or invasive carcinoma) in recently diagnosed patients. It helps to identify patients with ductal carcinoma in situ with low risk and identify whether they could be treated only with surgery or if they will benefit from radiation therapy after surgery.
The Oncotype DX® Colon Cancer Assay is a diagnostic test that evaluates 12 genes in a sample of colon tumor tissue. It quantifies the recurrence risk in stage II and stage III of colon cancer patients.
The Oncotype DX® Prostate Cancer Assay is a diagnostic test that evaluates 17 genes in a sample of prostate tumor tissue and predict their aggressiveness. Oncotype DX® helps identify which men with prostate cancer low clinical risk may remain on active surveillance and what men should receive immediate treatment after biopsy.